Cargando…

An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer

The introduction of monoclonal antibodies (mAbs) has largely improved treatment options for cancer patients. The ability of antitumor mAbs to elicit antibody-dependent cellular cytotoxicity (ADCC) contributes to a large extent to their therapeutic efficacy. Many efforts accordingly aim to improve th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmied, Bastian J., Riegg, Fabian, Zekri, Latifa, Grosse-Hovest, Ludger, Bühring, Hans-Jörg, Jung, Gundram, Salih, Helmut R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627285/ https://www.ncbi.nlm.nih.gov/pubmed/31181683 http://dx.doi.org/10.3390/cancers11060789

Ejemplares similares

Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
por: Schmied, Bastian J., et al.
Publicado: (2019)

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
por: Riegg, Fabian, et al.
Publicado: (2021)

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
por: Hagelstein, Ilona, et al.
Publicado: (2022)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
por: Märklin, Melanie, et al.
Publicado: (2019)

γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay
por: Seidel, Ursula Jördis Eva, et al.
Publicado: (2014)

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
por: Kauer, Joseph, et al.
Publicado: (2021)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

A “vicious cycle” of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?
por: Schmiedel, Benjamin Joachim, et al.
Publicado: (2013)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
por: Zekri, Latifa, et al.
Publicado: (2023)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
por: Hörner, Sebastian, et al.
Publicado: (2022)

Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab
por: Haen, Sebastian P., et al.
Publicado: (2016)

The challenges of translation
por: Salih, Helmut R, et al.
Publicado: (2019)

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
por: Lagassé, H.A. Daniel, et al.
Publicado: (2021)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
por: Heitmann, Jonas S., et al.
Publicado: (2021)

Signal transduction by the CD2 antigen in T cells and natural killer cells: requirement for expression of a functional T cell receptor or binding of antibody Fc to the Fc receptor, Fc gamma RIIIA (CD16)
Publicado: (1991)

CD133, Selectively Targeting the Root of Cancer
por: Schmohl, Jörg U., et al.
Publicado: (2016)

Delayed maturation of CD4- CD8- Fc gamma RII/III+ T and natural killer cell precursors in Fc epsilon RI gamma transgenic mice
Publicado: (1996)

Identification of CD318 (CDCP1) as novel prognostic marker in AML
por: Heitmann, Jonas S., et al.
Publicado: (2020)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
por: Heitmann, Jonas S, et al.
Publicado: (2020)

Murine natural killer cells express functional Fc gamma receptor II encoded by the Fc gamma R alpha gene
Publicado: (1989)

Activation of Fc receptor-bearing lymphocytes by immune complexes. II. Killer lymphocytes mediate Fc ligand-induced lymphokine production
Publicado: (1981)

GMP-conformant on-site manufacturing of a CD133(+) stem cell product for cardiovascular regeneration
por: Skorska, Anna, et al.
Publicado: (2017)

Physical and functional association of p56lck with Fc gamma RIIIA (CD16) in natural killer cells
Publicado: (1993)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

The Fc receptor on thymus-derived lymphocytes. III. Mixed lymphocyte reactivity and cell-mediated lympholytic activity of Fc- and Fc+ T lymphocytes
Publicado: (1976)

Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment
por: Castaneda, Diana Cadena, et al.
Publicado: (2018)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
por: Zekri, Latifa, et al.
Publicado: (2020)

Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI
por: Bohländer, Fabian, et al.
Publicado: (2021)

MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection
por: Zekri, Abdel-Rahman N., et al.
Publicado: (2018)

A Peptide-Fc Opsonin with Pan-Amyloid Reactivity
por: Foster, James S., et al.
Publicado: (2017)

Late Development of FcεRγ(neg) Adaptive Natural Killer Cells Upon Human Cytomegalovirus Reactivation in Umbilical Cord Blood Transplantation Recipients
por: Muccio, Letizia, et al.
Publicado: (2018)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133(high) to CD133(low) phenotype and reduces the CD133-related invasiveness
por: Brugnoli, Federica, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_18qpulb9kf9174hs303rg1cdu7